Skip to main content
. Author manuscript; available in PMC: 2009 Sep 22.
Published in final edited form as: J Allergy Clin Immunol. 2008 Jul;122(1):173–180.e2. doi: 10.1016/j.jaci.2008.05.025

TABLE III.

Association of MBL2 genotypes on CNS progression-free survival in children: Whole cohort

MBL2 genotypes compared RH (95% CI), P value
O/O vs A/O* 2.24 (1.00-5.01), .045
Adjusted† 2.77 (1.13-6.79), .03
Adjusted‡ 2.51 (1.09-5.81), .03
Adjusted§ 2.37 (1.02-5.50), .04
O/O vs A/A* 1.46 (0.98-2.16), .054
Adjusted† 1.63 (1.06-2.51), .03
Adjusted‡ 1.38 (0.92-2.06), .12
Adjusted§ 1.58 (1.04-2.41), .032
O/O vs A/O+A/A* 2.15 (1.00-4.64), .04
Adjusted† 2.74 (1.19-6.33), .02
Adjusted‡ 2.04 (0.94-4.46), .07
Adjusted§ 2.44 (1.10-5.39), .027
*

Unadjusted.

†

Adjusted for CD4+ lymphocyte count, HIV-1 RNA, treatments, race, and sex.

‡

Adjusted for CCR5-wt/Δ32, -59029-G/A, CX3CR1-249-V/I, -280-T/M, and SDF-1-180-G/A.

§

Adjusted for MBL2-H/L, MBL2-P/Q, and MBL2-X/Y.